Milos Miljkovic - Nov 14, 2024 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role
Chief Medical Officer
Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Milos Miljkovic
Stock symbol
RNAC
Transactions as of
Nov 14, 2024
Transactions value $
-$729,883
Form type
4
Date filed
11/18/2024, 07:28 PM
Previous filing
Apr 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAC Common Stock Options Exercise $113K +35K +191.54% $3.23 53.3K Nov 14, 2024 Direct
transaction RNAC Common Stock Sale -$565K -35K -65.7% $16.13 18.3K Nov 14, 2024 Direct F1
transaction RNAC Common Stock Options Exercise $64.6K +20K +109.45% $3.23 38.3K Nov 15, 2024 Direct
transaction RNAC Common Stock Sale -$343K -20K -52.26% $17.14 18.3K Nov 15, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNAC Stock Option (Right to Buy) Options Exercise -35K -40.92% 50.5K Nov 14, 2024 Common Stock 35K $3.23 Direct F3, F4
transaction RNAC Stock Option (Right to Buy) Options Exercise -20K -39.58% 30.5K Nov 15, 2024 Common Stock 20K $3.23 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.00 to $16.62. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.465. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The option is currently exercisable for 64,146 shares of Common Stock and becomes exercisable for the remaining 21,382 shares of Common Stock on September 13, 2025.
F4 On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.